CellFE
That's the actual company name. Assuming it's pronounced "selfie", that's just terrible. They're working on gene-editing delivery technology, and there's no real info on their
website, but they did raise a
seed round of $3.6M recently. Maybe some of that money will be spent on a branding consultant.
Erydel
This company is working on a very cool idea encapsulating drugs in a patient's
own red blood cells to improve deliverability.
Greenbone
Revolution Medicines
Their IPO went off without a hitch last week. $238M at $17/share. Instantly their shares leapt to $30 before settling at around $28. Nice work, underwriters! Bet they got paid about $15M to underprice this thing by $154M. All in a day's work.
Ipsen
To those of us unfamiliar with the world of mega-corporate accounting, the concept of a post-acquisition
write-down is a little strange. An asset was purchased, the company later realizes it's not worth as much, so they change their books to say they have less assets. It's mostly subjective and companies can basically just make up numbers.
Here we have Ipsen
writing down their $1.3B purchase of Clementia Pharmaceuticals
by $728M. The only reason they purchased Clementia was for their "largely derisked" drug palovarotene. 'Largely' is the operative word - it failed in phase 3 (leading to this write-down). And yet this asset is still worth $440M? Suuuuuuuuure.
